NeuroOne Medical Technologies (OTC:NMTC) announced that it was approved to uplist and begin trading on the Nasdaq market. Eden Prairie, Minn.-based NeuroOne expects trading to commence today at the open of the market, with the company trading under the “NMTC” ticker, according to a news release. The developer of surgical care options for patients suffering […]
NASDAQ
Second Sight facing Nasdaq delisting
Second Sight Medical (NSDQ:EYES) announced that it received a letter from the Nasdaq market confirming that it may face delisting. The Sylmar, Calif.-based developer and manufacturer of implantable visual prosthetics for blind individuals received the letter confirming that its common stock had closed below the $1 per share minimum required for continued listing for 30 consecutive […]
Acutus Medical launches IPO on Nasdaq
Cardiac mapping technology developer Acutus Medical announced that it priced its initial public offering on the Nasdaq market. The Carlsbad, Calif.-based company is offering 8,823,529 shares of its common stock at $18 per share, with gross proceeds expected to come in at approximately $158.8 million. Acutus Medical’s shares are expected to begin trading today (Aug.6, […]
Hancock Jaffe Labs in danger of losing NASDAQ listing
NASDAQ has warned Hancock Jaffe Laboratories (NSDQ:HJLI) that it is in danger of being delisted, but the company said in an SEC filing today that it intends to return to compliance. The warning, issued last week, said Hancock Jaffe did not have the minimum of $2.5 million in stockholders’ equity to merit its listing on the […]
Pavmed back in NASDAQ compliance
Pavmed (NSDQ:PAVM) said today that it has received formal notice from NASDAQ that it has returned to compliance with the stock exchange’s listing rule after 10 consecutive days with a closing bid price of at least $1 per share. NASDAQ warned the company in November that it was in danger of delisting due to poor […]
Pavmed threatened with stock exchange delisting
Pavmed (NSDQ:PAVM) is in danger of losing its listing on the NASDAQ exchange, according to a report filed with the Securities & Exchange Commission. In August last year, the FDA group reviewing Pavmed’s 510(k) application for its CarpX minimally invasive carpal tunnel release device asked the company to resubmit the application because the group hadn’t reached […]
Invuity closes $47.8m IPO
Invuity (NSDQ:IVTY) said it closed its initial public offering, raising approximately $47.8 million by offering 4.6 million shares at $12 per share. Leerink Partners, Piper Jaffray and Stifel were book-runners for the offering, with William Blair acting as co-manager, the company said. The IPO’s underwriters exercised a 600,000-share over-allotment, the San Francisco, Calif.-based surgical illumination device company […]
UPDATE: Invuity prices IPO at $12 per share, under the range
Invuity yesterday priced its initial public offering at $12 a share, under the range the advanced surgical lighting maker set earlier in June, looking to raise $48 million. Invuity shares were set to begin trading today under the “IVTY” symbol on the NASDAQ exchange, the company said, but plans for opening have been delayed until […]
InVivo hits the NASDAQ exchange
InVivo Therapeutics readies reverse split ahead of NASDAQ listing
